Leday: We've actually seen a strong shift in a positive direction, on our position within the hearts and minds of ASC owners and surgeons. Some of the things that ring true are that we're committed to creating a brand new ecosystem in the ambulatory surgery center space.

And what that means is looking beyond the amazing implants, like our Attune knee system, and looking to find more instruments and tools that can help with delivering value along with technology. (Also see "AAOS 2022 Roundup: Stryker, Zimmer Biomet, J&J’s DePuy Synthes, Canary Medical" - Medtech Insight, 29 March, 2022.)

It's not just the ability to create something that's ‘neat’ or differentiating or cutting-edge, but also figuring out how to create solutions that add value. And so that's something that makes a big difference in what DePuy Synthes brings to the table.

We’re looking to add value, not only in the implants and the actual instruments themselves that are traditionally deployed, but also in how we can support staff training and staff development – you've got this huge staffing challenge and need. And so the tenure and the expertise may or may not be there across the board in some of these newer ORs.

As we're adding additional sites of care you've still got hospitals that are standing up, but now you have ASCs that are providing new employment opportunities all across America. So how do we help bridge that divide and help educate their staff?

[How can we] help educate, particularly, surgeons on new techniques, new surgical applications and new instruments, like our Kincise [surgical automated system for total hip arthroplasty] and the Cuptimize [hip-spine analysis system], to name a few of the some of the things that we brought to the table.

Podcast Special: J&J's Andrie Leday Addresses ASC Market With Customized Approach

More from AI

More from Digital Technologies